Skip to main content
Amneal Pharmaceuticals
  • Corporate (opens in a new tab)
  • India (opens in a new tab)
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Sep 06, 2023
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
Sep 06, 2023
Amneal Receives First Product Approval in China
Sep 06, 2023
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
Aug 29, 2023
Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India
Aug 25, 2023
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
Aug 24, 2023
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
Aug 04, 2023
Amneal Reports Second Quarter 2023 Financial Results
Jul 26, 2023
Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics
Jul 06, 2023
Amneal to Report Second Quarter 2023 Results on August 4, 2023
Jul 03, 2023
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
Jul 03, 2023
Amneal Receives U.S. FDA Complete Response Letter for IPX203
Jun 15, 2023
Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals
Jun 14, 2023
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
May 24, 2023
Amneal to Participate at the 2023 Jefferies Healthcare Conference
May 16, 2023
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
May 05, 2023
Amneal Reports First Quarter 2023 Financial Results
Apr 17, 2023
Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference
Apr 17, 2023
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance
Apr 12, 2023
Amneal to Report First Quarter 2023 Results on May 5, 2023
Mar 02, 2023
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
Mar 02, 2023
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
Jan 31, 2023
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
Jan 04, 2023
Amneal Announces Strategic European Partnership with Orion Corporation

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.103.0.4 (opens in new window)
Back to top